ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation

Area of Science:

• Oncology
• Molecular Biology

Background:

• Osteosarcoma is a prevalent bone tumor with a poor prognosis.
• Effective combinatorial therapies are needed to overcome drug resistance in osteosarcoma.
• The role of Rho-associated coiled-coil forming protein kinase 2 (ROCK2) in osteosarcoma remains largely unexplored.

Purpose of the Study:

• To investigate the expression, clinicopathological significance, and functional role of ROCK2 in osteosarcoma.
• To elucidate the mechanism by which ROCK2 influences osteosarcoma progression and resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Main Methods:

• Analysis of ROCK2 expression in patient tissues and correlation with clinicopathological features and prognosis.
• In vitro and in vivo studies involving ROCK2 silencing to assess its impact on proliferation, apoptosis, and TRAIL sensitivity.
• Proteomics and O-GlcNAcylation analysis to determine the underlying molecular mechanisms.

Main Results:

• ROCK2 expression is upregulated in osteosarcoma tissues compared to adjacent tissues and correlates with tumor size and poor prognosis.
• ROCK2 silencing inhibits osteosarcoma cell proliferation and induces apoptosis.
• ROCK2 interferes with TRAIL-mediated apoptosis and promotes TRAIL resistance in osteosarcoma cells.
• ROCK2 influences osteosarcoma progression and TRAIL resistance by modulating O-GlcNAcylation via O-GlcNAc transferase degradation.

Conclusions:

• ROCK2 is a potential independent prognostic marker for osteosarcoma.
• ROCK2 plays a critical role in osteosarcoma progression and TRAIL resistance.
• Targeting ROCK2, potentially through modulation of O-GlcNAcylation, offers a promising therapeutic strategy for osteosarcoma management.